The invention relates to a method for the isolation of lymphocytes (in particular γδ T cells) from a non-haematopoietic tissue sample comprising the steps of: culturing the non-haematopoietic tissue sample in the presence of (a) Interleukin-2 (IL-2) or Interleukin-9 (IL-9); (b) Interleukin-5 (IL-15); and (c) Interleukin-21 (IL-21); and collecting a population of lymphocytes cultured from the non-haematopoietic tissue sample. Methods of subsequent expansion are provided, as well as populations of isolated cells obtained by the method and uses thereof.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

Provided is a method for producing an economical bovine serum composition containing many factors useful for cell proliferation. The method includes a step of performing an anticoagulation treatment of bovine whole blood with an anticoagulant, a step of obtaining a buffy coat and a fraction with a heavier specific gravity than that of the buffy coat from the anticoagulated whole blood, and a step of promoting and activating an interaction between the obtained leukocytes and platelets at a given temperature for not less than a given time to cause secretion or release of a humoral factor from the leukocytes and/or platelets and performing a recoagulation treatment of blood components including the humoral factor with a re-coagulating agent.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

The present invention provides methods of expanding T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded T cells and methods of using the expanded T cells (e.g., apart of an adoptive T cell therapy).

Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.

The present description relates to in vitro methods for culturing hematopoietic stem cells (HSCs) under mild hyperthermia conditions (e.g., between 38 C. and 40 C.) in the presence of a pyrimidoindole derivative agonist of hematopoietic stem cell expansion. The combined use of mild hyperthermia and the pyrimidoindole derivative act synergistically to promote expansion of CD34+ HSCs and/or differentiation into progenitor cells (e.g., megakaryocytic progenitors). The present description also relates to in vitro expanded cell populations of HSCs and/or progenitors, as well as uses thereof in therapy (e.g., transplantation).

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.